Evidence map›Paper›PMID 36575323›Full record

ReviewMolecular biology reports2023

The role of histone methylation in renal cell cancer: an update.

Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yanguang HouDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Yan YuanDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Yanze LiDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Lei WangDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Juncheng HuDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. hujc@whu.edu.cn.
Xiuheng LiuDepartment of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China. drliuxh@hotmail.com.
Renmin Hospital of Wuhan University · CNWuhan University · CN

Funding

Fundamental Research Funds for the Central Universities 2042021kf0105key research and development program of Hubei Province 2020BCB051National Natural Science Foundation of China 81972408
6 · The paper itself

Abstract

Renal cell carcinoma accounts for 2-3% of all cancers. It is difficult to diagnose early. Recently, genome-wide studies have identified that histone methylation was one of the functional classes that is most frequently dysregulated in renal cell cancer. Mutation or mis-regulation of histone methylation, methyltransferases, demethylases are associated with gene expression and tumor progression in renal cell cancer. Herein, we summarize histone methylations, demethylases and their alterations and mechanisms in renal cell cancer.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHistone-Lysine N-MethyltransferaseHistonesHumansMethylationHistone-Lysine N-MethyltransferaseHistonesDot1lEzh2Histone methylationLysine methyltransferasesRenal cell cancer

Identifiers

PMID36575323
OpenAlexW4313237576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.